RBC Capital analyst Arun Viswanathan downgraded Pactiv Evergreen (PTVE) to Sector Perform from Outperform with a price target of $18, up from $14, after the company entered into an agreement to merge with Novolex for $18 per share. RBC views the stock as fairly valued at current levels, noting the acquisition by Novolex has shareholder approval.
Don't Miss Our New Year's Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTVE: